Dr Syed Ismail Nawab John

Dr. N. Syed Ismail Nawab John specialises in advanced cancer surgeries and minimally invasive treatments at MGM Cancer Institute. His clinical practice includes laparoscopic and minimally invasive cancer surgery, with experience in the surgical management of breast, gastrointestinal, head and neck, thyroid, gynaecological and soft tissue tumours. He focuses on patient-centred cancer care and advanced surgical techniques.

Educational Qualifications:

• MBBS – Tirunelveli Medical College – 2002
• MD (Radiotherapy) – Madras Medical College, Chennai – 2006
• DM (Medical Oncology) – Madras Medical College, Chennai – 2013
• DNB (Medical Oncology) – Madras Medical College, Chennai – 2016

Professional Experience:

• Currently working as Clinical Lead and Senior Consultant – Medical Oncology at MGM Cancer Institute, Chennai.
• Over 15 years of experience in treating solid tumours, blood cancers and paediatric cancers.
• Specialised in the management of solid tumours, haematological malignancies and paediatric cancers.
• Works closely with multidisciplinary oncology teams, including surgical oncology, to develop personalised treatment plans.
• Expertise in stem cell transplantation for complex blood disorders and cancers.
• Experienced in bringing chemotherapy, immunotherapy and targeted therapies into clinical practice.
• Serves as a Principal Investigator in clinical trials and contributes to cancer research.

Awards and Achievements:

• Gold Medallist – DM (Medical Oncology).
• Distinguished alumnus of Madras Medical College.
• Actively contributes to cancer research and the adoption of advanced oncology therapies.

Professional Memberships:

• Indian Society of Oncology (ISO)
• Indian Society of Gastroenterology
• Society of Gastrointestinal Endoscopy of India

Research and Presentations:

• Actively contributes to cancer research.
• Involved in bringing newer cancer treatment approaches into clinical practice.
• Research interests include advanced therapies, precision medicine, chemotherapy, immunotherapy and targeted therapies.